Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of Utah
ClinicalTrials.gov Identifier:
NCT00795132
First received: November 19, 2008
Last updated: July 23, 2013
Last verified: July 2013
Results First Received: January 30, 2012  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Acute Leukaemia
Chronic Disease
Leukemia
Myelodysplasia
Lymphoma
Interventions: Drug: Busulfan
Drug: Anti-Thymocyte Globulin
Drug: Fludarabine
Drug: Cyclosporine
Drug: Mycophenolate mofetil

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
All Study Participants This group contains data from all groups (Related Bone marrow Peripheral Blood Stem Cell (BM PBSC), Unrelated Peripheral Blood Stem Cell (PBSC), and Unrelated Cord blood.

Participant Flow:   Overall Study
    All Study Participants  
STARTED     47  
COMPLETED     44  
NOT COMPLETED     3  
Death                 1  
Relapse                 2  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
All Study Participants This group contains data from all groups (Related Bone marrow Peripheral Blood Stem Cell (BM PBSC), Unrelated Peripheral Blood Stem Cell (PBSC), and Unrelated Cord blood.

Baseline Measures
    All Study Participants  
Number of Participants  
[units: participants]
  47  
Age  
[units: participants]
 
<=18 years     35  
Between 18 and 65 years     12  
>=65 years     0  
Age  
[units: years]
Mean ± Standard Deviation
  13  ± 9.899  
Gender  
[units: participants]
 
Female     22  
Male     25  
Region of Enrollment  
[units: participants]
 
United States     35  
Canada     8  
Australia     4  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of High Risk Pediatric Patients With Successful Sustained Donor Engraftments   [ Time Frame: 24 months ]

2.  Secondary:   Two Year Overall Survival   [ Time Frame: 24 months ]

3.  Secondary:   Number of Participants Who Experienced Transplantation-related Mortality (TRM)   [ Time Frame: 24 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Participants who experienced early relapse or death before engraftment were excluded from analysis.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Dr. Michael Pulsipher
Organization: University of Utah
phone: 801-588-2680
e-mail: michael.pulsipher@hsc.utah.edu


No publications provided by University of Utah

Publications automatically indexed to this study:

Responsible Party: University of Utah
ClinicalTrials.gov Identifier: NCT00795132     History of Changes
Other Study ID Numbers: HCI12073
Study First Received: November 19, 2008
Results First Received: January 30, 2012
Last Updated: July 23, 2013
Health Authority: United States: Institutional Review Board